Physician profile
Gilberto Alvarez
NPI 1598303984
$1,936.92
in general payments reported to CMS, 2019-2025
26 companies · $699 in 2025
The $699 reported for 2025 was more than what 88% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $220 · 2023: $729 · 2024: $289 · 2025: $699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,717.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $766.95 | 2023-2024 | Vtama |
| Leo Pharma INC. | $402.70 | 2025 | Anzupgo, Adbry |
| Grt US Holding, INC. | $122.55 | 2022 | |
| Pfizer INC. | $77.85 | 2023-2024 | |
| Botanix Sb INC | $67.88 | 2025 | Sofdra |
| Almirall LLC | $60.45 | 2022 | |
| Merz North America, INC. | $60.44 | 2025 | |
| Alpha Cognition USA, INC. | $49.03 | 2025 | Zunveyl |
| Glaxosmithkline, LLC. | $40.68 | 2023 | Trelegy Ellipta |
| Neurocrine Biosciences, INC. | $35.42 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $26.77 | 2024 | Rexulti |
| Abbott Laboratories | $24.83 | 2022 | |
| Boston Scientific Corporation | $23.45 | 2023 | Watchman Access System |
| Novo Nordisk INC | $23.22 | 2023 | Ozempic, Rybelsus |
| Ucb, INC. | $22.87 | 2025 | Bimzelx |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $22.56 | 2025 | |
| Lilly USA, LLC | $20.82 | 2025 | Mounjaro |
| Lnhc, INC | $17.62 | 2025 | Zelsuvmi |
| Horizon Therapeutics Plc | $15.99 | 2023 | Krystexxa |
| Fidia Pharma USA INC. | $14.79 | 2023 | Hym/Hyn |
| Astrazeneca Pharmaceuticals Lp | $14.38 | 2024 | Breztri |
| Mayne Pharma Commercial LLC | $13.74 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.93 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gilberto Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.